Sichuan Difit Pharmaceutical Co Ltd.

A randomized, open, two-period crossover, single oral trial design was used to compare the differences in absorption extent and absorption rate of ursodeoxycholic acid capsules (specification: 0.25 g) provided by Sichuan Difit Pharmaceutical Co., Ltd. and ursodeoxycholic acid capsules (trade name: Ursofalk®/Ursofalk®; specification: 250 mg) produced by Losan Pharma GmbH, a licensed drug of Dr. Falk Pharma GmbH, in healthy Chinese people under the condition of postprandial administration, and to evaluate the safety of ursodeoxycholic acid capsules (specification: 0.25 g) provided by Sichuan Difit Pharmaceutical Co., Ltd.

To investigate whether there are differences in the extent and rate of absorption between the test preparation vonoprazan fumarate tablets (Sichuan Difit Pharmaceutical Co., Ltd., specification: 20 mg) and the reference preparation vonoprazan fumarate tablets (trade name: Walker, Takeda Pharmaceutical Company Limited., specification: 20 mg) taken orally on an empty stomach and after a meal in healthy subjects, to evaluate the bioequivalence of the test preparation and the reference preparation when administered on an empty stomach and after a meal, and to observe the safety of the test preparation and the reference preparation in healthy subjects.

A randomized, open, two-period crossover, single oral trial design was used to compare the differences in absorption extent and absorption rate of ursodeoxycholic acid capsules (specification: 0.25 g) provided by Sichuan Difit Pharmaceutical Co., Ltd. and ursodeoxycholic acid capsules (trade name: Ursofalk®/Ursofalk®; specification: 250 mg) produced by Dr. Falk Pharma GmbH (licensed by Losan Pharma GmbH) in healthy Chinese people under fasting and postprandial administration conditions, and to evaluate the safety of ursodeoxycholic acid capsules (specification: 0.25 g) provided by Sichuan Difit Pharmaceutical Co., Ltd.